Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Alcon Inc.

In a report released on December 10, Matt Miksic from Barclays maintained a Hold rating on Alcon, with a price target of $86.00. The company’s shar...

Barclays Sticks to Their Hold Rating for Alcon (ALC)

In a report released on December 9, Baptiste de Leudeville from Kepler Capital maintained a Hold rating on Catana Group SA, with a price target of ...

Kepler Capital  Keeps Their Hold Rating on Catana Group SA (2HU)

Kepler Capital analyst Baptiste de Leudeville maintained a Buy rating on Carbios SA on December 3 and set a price target of €14.00. The company’s s...

Carbios SA (COOSF) Receives a Buy from Kepler Capital

In a report released yesterday, Craig Wong-Pan from RBC Capital maintained a Hold rating on Alcidion Group Limited, with a price target of A$0.12. ...

RBC Capital Sticks to Their Hold Rating for Alcidion Group Limited (ALC)

In a report released today, Thomas Wakim from Bell Potter maintained a Buy rating on Alcidion Group Limited, with a price target of A$0.14. Accordi...

Bell Potter Remains a Buy on Alcidion Group Limited (ALC)

Alternus Clean Energy ( ($ALCE) ) has released a notification of late filing. Alternus Clean Energy, Inc. has announced a delay in filing its Form ...

Alternus Clean Energy Delays Q3 2025 Report

In a report released on November 14, Leland Gershell from Oppenheimer maintained a Buy rating on CalciMedica, with a price target of $20.00. The co...

Oppenheimer Reaffirms Their Buy Rating on CalciMedica (CALC)

Alcidion Group Limited ( ($AU:ALC) ) just unveiled an update. Alcidion Group Limited has expanded its contract with Leidos Australia to enhance the...

Alcidion Expands Contract with Leidos Australia, Boosting Revenue and Market Position

Alchemy Investments Acquisition Corp 1 Class A ( ($ALCY) ) has released a notification of late filing. Alchemy Investments Acquisition Corp 1 Class...

Alchemy Investments Faces Delay in 10-Q Filing

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Alcon yesterday and set a price target of $80.00. The company’s shares closed yeste...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALC	$78.80	+0.05%	1.09M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALC	$78.80	+0.1%	1.09M
3
4
5
6

ALC

ALC

Get Alcon Inc. Data in Excel

Get Alcon Inc. Data in Excel